1569: Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study

Jing Li¹, Yang Zhao², Yang Yu³, Xianan Jian⁴, Yanhong Wang⁵, yunjiao yang⁶, Xinping Tian⁷, Mengtao Li⁷ and Xiaofeng Zeng⁷, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China, ³The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China, ⁴Puyang Oilfield General Hospital, Puyang, China, ⁵Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁷Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Background/Purpose: To compare the efficacy and safety of tofacitinib and tocilizumab in patients with Takayasu arteritis (TAK) in real world situation.

Methods: A post-hoc analysis was conducted in 84 patients with TAK registered in the Chinese Registry of Systemic Vasculitis (CRSV) cohort [median age 26 years (interquartile range 22-32), 76 (90%) females] were included (Figure 1). Patients who were treated with either tofacitinib (n=42) or tocilizumab (n=42) were followed up regularly according to the pre-set protocol. Complete response was defined as both clinically and imagine remission with the dosage of prednisone ≤ 10mg daily and normal acute-phase reactant, while partial response were the same with complete response except that ESR was less than 40mm/h or hs-CRP (hypersensitive C reactive Protein) higher than 16mg/L or the acute-phase reactant decreased by more than 50% compared to the baseline.

Results: The baseline clinical features and demographic date were similar in these two groups (Table 1). Complete response at 6 months was found in 18/27 (67%) patients treated with tofacitinib and 22/32 (69%) with tocilizumab, and rates of overall response in intention-to-treat (ITT) populations were 43% and 52% respectively (P>0.05). At 12, 18 and 24 months, the rates of overall response in ITT population (41%, 24% and 14% vs. 41%, 36% and 29%) and in per-protocol (PP) population (77%, 71% and 75% vs.65%, 83% and 80%) were similar in patients treated with tofacitinib to those with tocilizumab (Table 2). There were no significant difference found in the changes of ESR, CRP, TNFa, dose of glucocorticoid, mural thickness and lumen diameters of common carotid and subclavian arteries in these two groups. And the cumulative incidences of relapse, treatment failure, and drug retention were similar, too (Figure 1). The drug retention rates at 6, 12, 18 and 24 months in patients treated with tofacitinib and tocilizumab were 64%, 52%, 33% and 19% vs. 76%, 60%, 43% and 36%, respectively.

Six (14%) adverse events occurred in the tofacitinib treatment group (including 3 patients with herpes zoster infection, 1 with pulmonary infection, 1 with headache and 1 with abdominal pain) and 6 (14%) occurred in the tocilizumab treatment group (including 2 patients with back pain, 1 with acute pancreatitis, 1 with pulmonary infection, 1 with vomiting and 1 with hepatic dysfunction).

Conclusion: Tofacitinib and tocilizumab are both effective for refractory TAK with similar response rates, cumulative incidences of relapse, treatment failure, and drug retention. Both medications may be effective alternatives for patients who failed to respond to traditional immunosuppressive agents.








J. Li: None; Y. Zhao: None; Y. Yu: None; X. Jian: None; Y. Wang: None; y. yang: None; X. Tian: None; M. Li: None; X. Zeng: None.